Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

82.87EUR
24 Mar 2017
Change (% chg)

€-0.43 (-0.52%)
Prev Close
€83.30
Open
€83.11
Day's High
€83.11
Day's Low
€82.42
Volume
1,444,188
Avg. Vol
2,543,661
52-wk High
€83.86
52-wk Low
€62.50

Latest Key Developments (Source: Significant Developments)

China Resources Sanjiu Medical & Pharma plans framework agreement with Sanofi
Thursday, 1 Dec 2016 11:20pm EST 

China Resources Sanjiu Medical & Pharmaceutical Co Ltd <000999.SZ> : Says it plans to sign framework agreement with Sanofi SA on consumer health business .Says it plans to set up JV in China with Sanofi's unit.  Full Article

Sanofi says receives FDA approval of Soliqua 100/33
Monday, 21 Nov 2016 07:06pm EST 

Sanofi Sa : Sanofi receives FDA approval of Soliqua(tm) 100/33, for the treatment of adults with type 2 diabetes .Says Soliqua 100/33 will be available in U.S. retail pharmacies in January 2017.  Full Article

Sanofi says receives FDA approval of Soliqua 100/33
Monday, 21 Nov 2016 06:20pm EST 

Sanofi Sa : Sanofi receives FDA approval of Soliqua(tm) 100/33, for the treatment of adults with type 2 diabetes .Says Soliqua 100/33 will be available in U.S. retail pharmacies in January 2017.  Full Article

Regeneron and Sanofi Present Results from late-stage Monarch study at American College of Rheumatology Annual Meeting
Wednesday, 16 Nov 2016 08:00am EST 

Regeneron Pharmaceuticals Inc : Regeneron Pharmaceuticals-In MONARCH study, sarilumab monotherapy showed superiority over adalimumab monotherapy in adults with active rheumatoid arthritis .Press Release - Regeneron and Sanofi present results from phase 3 MONARCH study of investigational sarilumab at American College of Rheumatology Annual Meeting.  Full Article

Alnylam pharmaceuticals announces Sanofi Genzyme opt-in decision
Monday, 14 Nov 2016 08:00am EST 

Alnylam Pharmaceuticals Inc : Alnylam Pharmaceuticals announces Sanofi Genzyme opt-in decision for co-development and co-commercialization of fitusiran in hemophilia and rare bleeding disorders . Sanofi genzyme elects not to opt in for ALN-AS1 in acute hepatic porphyrias . Alnylam intends to commercialize ALN-AS1 globally upon product approval . Co, Sanofi Genzyme will co-develop and co-commercialize fitusiran in U.S., Canada, Western Europe . Alnylam pharma - Sanofi Genzyme will be required to make payments up to $75 million upon achievesanment of development, regulatory milestones for fitusiran .On track to initiate fitusiran Phase 3 program in early 2017.  Full Article

Selecta Biosciences receives exclusive rights to peanut allergy and celiac disease programs
Thursday, 10 Nov 2016 06:45am EST 

Selecta Biosciences Inc : Selecta biosciences receives exclusive rights to peanut allergy and celiac disease programs . Selecta biosciences - deal follows sanofi's strategic review of its research and development portfolio, which resulted in decision to exit collaboration with selecta . Selecta biosciences inc - transition of discovery programs is not expected to have a material impact on selecta's cash runway .Selecta biosciences inc - intends to partner or out-license its svp technology for indications that are outside core areas of focus.  Full Article

Myriad RBM announces agreement with Sanofi
Tuesday, 25 Oct 2016 07:05am EDT 

Myriad Genetics Inc : Announces an agreement with Sanofi to measure predictive cardiovascular biomarkers in patients with diabetes . Financial terms of deal were not disclosed .Under agreement, Sanofi will provide approximately 5,300 serum samples from elixa trial.  Full Article

Sanofi reports open market purchase of 450,000 shares of Myokardia
Wednesday, 5 Oct 2016 09:00am EDT 

Sanofi SA : Sanofi reports open market purchase of 450,000 shares Of Myokardia Inc for $15/Share on Oct 3, 2016 .Sanofi's open market purchase of 450,000 shares of myokardia inc made on Oct 3 represents an indirect ownership in Myokardia.  Full Article

Immune Design Announces Advancement of First GLAAS-based Allergy Program into Clinical Development
Wednesday, 28 Sep 2016 08:00am EDT 

Immune Design Corp : Application of co's glaas discovery platform in Sanofi's phase 1 clinical trial evaluating a candidate for treatment of peanut allergy . Trial follows exclusive license agreement with co to discover, develop, commercialize products to treat a peanut allergy using GLAAS .Has received undisclosed milestone payment for start of trial, is eligible to receive future development,commercialization milestones.  Full Article

Sanofi says BARDA grants $43.2 million to Sanofi Pasteur for Zika
Monday, 26 Sep 2016 11:05am EDT 

Sanofi : BARDA grants $43.2 million usd to Sanofi Pasteur for Zika . Beyond funding provided by BARDA for two phase i/ii clinical trials, there is an option for continuing support through phase iii . BARDA and U.S. Department of health and human services has agreed to a proposal to fund manufacture of Zika vaccine for phase ii development ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

More From Around the Web

Doctors, patients urge court to reject ban on cholesterol drug sales

A group of doctors and patients are urging a federal appeals court to overturn a lower court order banning sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent after Amgen Inc won a patent lawsuit against them.